Kymera Therapeutics (KYMR) Asset Writedowns and Impairment (2024 - 2025)
Kymera Therapeutics' (KYMR) quarterly Asset Writedowns and Impairment came in at $45000.0 in Q4 2025, down 98.83% on a QoQ basis from $3.9 million in Q3 2025.
Kymera Therapeutics (KYMR) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Kymera Therapeutics (KYMR) has 2 years of Asset Writedowns and Impairment data on file, last reported at $45000.0 in Q4 2025.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $45000.0 in Q4 2025; TTM through Dec 2025 was $3.9 million, a 20.81% decrease from a year earlier, with the FY2025 full-year figure at $3.9 million, down 20.81% from the prior year.
- Asset Writedowns and Impairment for Q4 2025 stood at $45000.0, down from $3.9 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for KYMR reached as high as $4.9 million in Q1 2024 and fell as low as $45000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Kymera Therapeutics | 10.77 Bn | 10.12 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 45,000.00 |
| Dec 31, 2025 | 45,000.00 |
| Sep 30, 2025 | 3.86 Mn |
| Sep 30, 2025 | 3.86 Mn |
| Mar 31, 2024 | 4.93 Mn |
| Mar 31, 2024 | 4.93 Mn |